SiteMap
HOME
ABOUT US
Company Profile Company Philosophy Development History Company Honor Video Center
PRODUCT CENTER
Drug Class Medical Instruments
RESEARCH CENTER
R&D Strength Pipeline Products Intellectual Property
NEWS CENTER
Company news
INVESTOR RELATIONSHIP
Company Governance Information Disclosure Contact Detail
CAREER DEVELOPMENT
Talent Concept Recruitment positions
CONTACT US
16.24
上交所上市企业股票
代码：111111
WeChat public account
Jiuyuan Gene
With innovation as the guide，and market as the support
build a leading biopharmaceutical company
A high and new technology company, specialized in R&D,manufacture and sales of
biopharmaceuticals and medical devices.
Jiuyuan Gene
Taking gene engineering as orientation
Rendering service to human health
A high and new technology company, specialized in R&D,manufacture and sales of
biopharmaceuticals and medical devices.
Jiuyuan Gene
ABOUT US
Jiuyuan Gene
Taking gene engineering as orientation,
Rendering service to human health

Hangzhou Jiuvuan Genetic Biopharmaceutical Co., Ltd.( Stock Code: 02566.Hk)is a new high-tech enterprise, specialized in R&D,manufacture and sales of biopharmaceutical and medical device. We focus on four fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology and hematology. The company was founded in December 1993, as one of the earliest gene engineering pharmaceutical enterprises in Zhejiang province as well as in China.In November 2024, Jiuyuan Gene was listed on the Hong Kong Stock Exchange.

 

Jiuyuan Gene always upholds the concept "Taking gene engineering as orientation, Rendering service to human health , to pursue innovation and to strive for excelence. In October 1996, the company took the lead in successful development and industrialization of a leukocyte promotion medicine....

View More
Product Center

PRODUCT CENTER

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has actively propelled the progress of biopharmaceutical industrialization, gradually developed a series of products including JILIFEN, JIPAILIN, JIJUFEN, YINUOJIA, JIOUTING and GUYOUDAO.

View More
DRUG CLASS
DRUG CLASS
DRUG CLASS
Actively propel the progress of biopharmaceutical industrialization, gradually developed a series of products including JILIFEN, JIPAILIN, JIJUFEN, YINUOJIA, JIOUTING.
JILIFEN JIJUFEN JITANSU JIFUWEI YINUOJIA JIPAILIN JIOUTING JIXINFEN JILIXIN
MEDICAL DEVICE
MEDICAL DEVICE
MEDICAL DEVICE
Bone repairing material, the only quantitative rhBMP-2 bone repairing material in China, a new generation of genetically engineered bone repairing material.
GUYOUDAO
NEWS CENTER
JIUYUAN NEWS
View More
Jiuyuan Gene
HISTORY
DEVELOPMENT HISTORY
查看更多
1993.
  • Our company was registered and established in December.
1996.
  • Our company lanuched the frist product JLIFEN(Filgrastim) in October.
1997.
  • Our company obtained NDA approval for JIPAILIN(Low molecular weight heparin sodium injection) in June.
2003.
  • Our company obtained NDA approval for JIJUFEN(Human interleukin-11 for injection) in September.
2006.
  • Our company obtained NDA approval for YINUOJIA(Enoxaparin sodium injection) in July.
2008.
  • Our company was rated as a national High and New tech enterprise.
2009.
  • Our company obtained NDA approval for GUYOUDAO(BMP-2).
2011.
  • Our company established the Hangzhou Academician Expert Workstation.
2022.
  • Our company obtained NDA approval for JIFUWEI(Fulvestrant injection).
2023.
  • Our company obtained NDA approval for JITANSU(Fosaprepitant dimeglumine for injection).
  • Our company obtained NDA approval for Liraglutide.
2024.
  • In April,Our company's biosimilar semaglutide was the first company to apply for production license in China.
  • On November 28, the company was listed on the Hong Kong Stock Exchange
HISTORY
DEVELOPMENT HISTORY
查看更多
  • 1993.
    Our company was registered and established in December.
  • 1996.
    Our company lanuched the frist product JLIFEN(Filgrastim) in October.
  • 1997.
    Our company obtained NDA approval for JIPAILIN(Low molecular weight heparin sodium injection) in June.
  • 2003.
    Our company obtained NDA approval for JIJUFEN(Human interleukin-11 for injection) in September.
  • 2006.
    Our company obtained NDA approval for YINUOJIA(Enoxaparin sodium injection) in July.
  • 2008.
    Our company was rated as a national High and New tech enterprise.
  • 2009.
    Our company obtained NDA approval for GUYOUDAO(BMP-2).
  • 2011.
    Our company established the Hangzhou Academician Expert Workstation.
  • 2022.
    Our company obtained NDA approval for JIFUWEI(Fulvestrant injection).
  • 2023.
    Our company obtained NDA approval for JITANSU(Fosaprepitant dimeglumine for injection).
    Our company obtained NDA approval for Liraglutide.
  • 2024.
    In April,Our company's biosimilar semaglutide was the first company to apply for production license in China.
    On November 28, the company was listed on the Hong Kong Stock Exchange